Fluidda news

INTRODUCTION

Gabriel Krestin received his MD from the University of Cologne, Germany where he also specialized in radiology, in 1981 and his PhD (Habilitation) in 1989. From 1990–1997, he worked at the University Hospital in Zürich/CH, including a period as acting chairman of the Department of Radiology. In 1997 he moved to Erasmus MC in Rotterdam, Netherlands where he was the Professor and Chairman of the Department of Radiology & Nuclear Medicine unti

Fluidda, leader in the field of Functional Respiratory Imaging and developer of the medical device Broncholab®, today announced an exclusive collaboration with Nanopharm, an Aptar Pharma company and a leader in contract research and development services for orally inhaled and nasal drug products (OINDPs). The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administrat

Broncholab™, developed and implemented by Fluidda, is a platform where CT-scan data of individual persons can be uploaded and analyzed with FRI-technology. The result of this analysis is then sent to the attending physician alone, observing all privacy requirements.

Broncholab provides physicians with reproducible CT values for pulmonary tissue for providing quantitative support for diagnosis and follow-up examination. Broncholab can be used to support physicians in the diagnosi

To address the need for better chronic respiratory care, Prof De Backer, emeritus Professor Pulmonology at the University of Antwerp and Chairman of The board of FLUIDDA NV, has opened a private clinic in Belgium near the Fluidda headquarters in Kontich, Belgium.

The clinic uses a multidisciplinary approach for chronic respiratory failure. Care at this private clinic can involve exercise rehabilitation, non-invasive ventilation, oxygen treatments, sleep studies, and the

“Quantitative imaging of the airways, for example with functional respiratory imaging (FRI), is evolving from a research tool towards clinical applications” ,Dr. Maarten van den Berge, thoracic physician at the University of Groningen,  states in a recently published interview.

“For the past 15 years, FEV1 measurements have been the gold standard and are included in the GOLD guidelines. Nowadays, medical professionals view the patient in